ARVINAS, INC. Depreciation
ARVINAS, INC. (ARVN) reported Depreciation of $700.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-05-01
- ARVINAS, INC. depreciation for the quarter ending 2025-03-31 was $700.00K, a 41.67% decline year-over-year.
- ARVINAS, INC. depreciation for the quarter ending 2024-03-31 was $1.20M.
- ARVINAS, INC. depreciation for the quarter ending 2019-03-31 was $246.16K, a 100.08% increase year-over-year.
- ARVINAS, INC. depreciation for the quarter ending 2018-12-31 was $222.95K, a 120.68% increase year-over-year.
- ARVINAS, INC. depreciation for fiscal 2024 was $4.60M, a 4.17% decline from fiscal 2023.
- ARVINAS, INC. depreciation for fiscal 2023 was $4.80M, a 23.81% decline from fiscal 2022.
- ARVINAS, INC. depreciation for fiscal 2022 was $6.30M, a 31.25% increase from fiscal 2021.
- ARVINAS, INC. depreciation for fiscal 2021 was $4.80M, a 50.00% increase from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $700.00K 10-Q · filed 2025-05-01 | ||||
| 2024-12-31 | $4.60M 10-K · filed 2025-02-11 | ||||
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | $4.80M 10-K · filed 2025-02-11 | ||||
| 2022-12-31 | $6.30M 10-K · filed 2025-02-11 | ||||
| 2021-12-31 | $4.80M 10-K · filed 2024-02-27 | ||||
| 2020-12-31 | $3.20M 10-K · filed 2023-02-23 | $3.17M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $1.60M 10-K · filed 2022-02-28 | $1.56M 10-K · filed 2020-03-16 | |||
| 2019-03-31 | $246.16K 10-Q · filed 2019-05-09 | $469.11K derived: sum of 2 quarters · filed 2021-03-01 | $660.65K derived: sum of 3 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $222.95K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $414.50K derived: sum of 2 quarters · filed 2021-03-01 | $706.00K 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $191.55K 10-Q · filed 2018-11-14 | $483.05K 10-Q · filed 2018-11-14 | |||
| 2018-03-31 | $123.03K 10-Q · filed 2019-05-09 | $224.06K derived: sum of 2 quarters · filed 2019-05-09 | $316.20K derived: sum of 3 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $101.03K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $193.18K derived: sum of 2 quarters · filed 2019-03-26 | $347.39K 10-K · filed 2019-03-26 | ||
| 2017-09-30 | $92.15K 10-Q · filed 2018-11-14 | $246.37K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |